New Pooled Analysis Found Lantus(R) Reduced A1C and FBG Levels in Adults Over 65 with Type 2 Diabetes Compared to Those Treated with NPH
Posted on: Saturday, 6 June 2009, 10:00 CDT
- A1C and FBG Results for Patients 65 and Under Treated with Lantus and NPH were Similar -
Patients over 65 who received Lantus(R) had statistically significantly greater A1C reductions, with an average decrease of 1.21% in the Lantus(R) group versus 0.99% in the NPH group (P<0.05). These older patients also experienced statistically significantly greater FBG reductions with Lantus(R) treatment than NPH (92 mg/dL versus 85 mg/dL, P<0.05). The number of symptomatic hypoglycemic events per patient year in these older patients was 2.2 for Lantus(R) and 2.4 for NPH, with 0.01 severe hypoglycemic events for Lantus(R) and 0.03 for NPH.
The rate of nocturnal hypoglycemia was statistically significantly lower with Lantus(R) than NPH insulin in both age groups (1.1 versus 2.3 average events per patient year [P<0.0001] in patients < or = o 65 years old; and 1.3 versus 2.7 average events per patient year [P<0.005] in patients >65 years old).
About the Study
Twenty-two sanofi-aventis-sponsored, randomized clinical trials in patients with type 2 diabetes were screened. Only studies that met the following criteria were included in the analysis: all patients in these trials were insulin naive, had diagnosed type 2 diabetes, and were treated with a basal insulin only (Lantus(R) or NPH insulin). Duration of treatment in all studies was 24 weeks.
Data were pooled from 4 similar, international, multisite, randomized clinical trials comparing the safety and efficacy of the addition of Lantus(R) or NPH insulin to oral hypoglycemic drugs in patients with uncontrolled hyperglycemia. All patient-level data were combined from the 4 studies that met these criteria.
Studies were compared for A1C reduction and hypoglycemic events at the end of 24 weeks in patients < or = 65 (Lantus(R) [n=831] versus NPH [n=859]) versus >65 years (Lantus(R) [n=215] versus NPH [n=236]). Hypoglycemia was defined as self-monitored blood glucose (SMBG) <70 mg/dL with associated symptoms and severe hypoglycemia was defined as a hypoglycemic event requiring assistance of another person and a blood glucose level <50 mg/dL for 3 studies and <56 mg/dL for the fourth study or with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration. Combined data were analyzed using fixed- and random-effects models, and controlled for age category, treatment, study, and baseline A1C and BMI.
About Diabetes
Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin, the hormone needed to transport glucose (sugar) from the blood into the cells of the body for energy. More than 230 million people worldwide are living with the disease and this number is expected to rise to a staggering 350 million within 20 years. It is estimated that nearly 24 million Americans have diabetes, including an estimated 5.7 million who remain undiagnosed. At the same time, approximately 40 percent of those diagnosed are not achieving the blood sugar control target of A1C <7 percent recommended by the ADA. The A1C test measures average blood glucose levels over the past two- to three-month period.
About sanofi-aventis
Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in
For more information, www.sanofi-aventis.us or www.sanofi-aventis.com
U.S. Contact: Carrie Melia Carrie.melia@sanofi-aventis.com 908-981-6486US.GLA.09.05.131 (C) 2009 sanofi-aventis U.S. LLC
* Based on TRx data from IMS Health, National Prescription AuditTM (Next Generation Prescription Methodology). Time period:
SOURCE sanofi-aventis
Source: PR Newswire
Related Articles
- Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R)
- Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated With AERx(R) Insulin Diabetes Management System (iDMS)
- Sanofi-Aventis' SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
- MedApps D-PAL(TM) Remote Patient Monitoring System for Diabetes Cleared for Over-the-Counter Use By FDA
- New Study Demonstrates Colesevelam HCl Lowers Both A1C And LDL Cholesterol in Patients With Uncontrolled Type 2 Diabetes Mellitus on Metformin-Based Regimen
- New Study Confirms WelChol Improves Glycemic Control in Patients With Uncontrolled Type 2 Diabetes Mellitus on Insulin
- Type 2 Diabetes Patients on Technosphere Insulin Exhibited No Adverse Effect on Pulmonary Function With Significant HbA1c Reductions, and Showed Significant Weight Reduction Compared to Injected Insulin Analog
- Auxilium Pharmaceuticals Announces Top-Line Results From Phase IV Trial of Testim(R) in Patients With Type II Diabetes
- Type 1 Diabetes Patients on Technosphere Insulin Showed HbA1c Improvements, Low Post-Prandial Glucose Fluctuations, and Weight Loss
- Cost-Effectiveness in Italy of Preventive Treatment With Ramipril in Patients at High Risk of Cardiovascular Events
 |
 |
User Comments (0)
RSS Feeds